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ABSTRACT
 Context: Middle ear barotrauma (MEB) is common 
during chamber compression in hyperbaric oxygen 
therapy. However, little evidence exists on an optimal 
compression protocol to minimize the incidence and 
severity of MEB.
 Objective: To compare the incidence of MEB during 
hyperbaric oxygen therapy using two different chamber 
compression protocols.
 Design: Double-blinded, randomized controlled trial.
 Setting: Hyperbaric Medicine Unit, The Townsville 
Hospital, Queensland, Australia, September 2012 to 
December 2014.
 Patients: 100 participants undergoing their first 
hyperbaric oxygen therapy session.
 Intervention: Random assignment to a staged 
(n=50) or a linear (n=50) compression protocols. 
Photographs of tympanic membranes were taken 
pre- and post-treatment and then graded. Middle ear 
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barotrauma was defined as an increase of at least one 
grade on a modified TEED scale.
 Results: The observed MEB incidence under the 
staged protocol was 48% compared to 62% using the 
linear protocol (P=0.12, exact one-sided binomial test), 
and thus the staged protocol did not show a significant 
improvement in MEB. However, the staged protocol 
resulted in significantly less severe deteriorations in 
MEB grades when compared to the linear protocol 
(P=0.028, exact one-sided Mann-Whitney type test). 
 Conclusion: The use of the assessed staged 
compression protocol for the first hyperbaric oxygen 
treatment showed no significant effect on the overall 
incidence of MEB when compared to the gold standard 
linear protocol but resulted in a significant improve-
ment in the severity of the experienced MEBs. Further 
studies are needed to elucidate an optimal compression 
protocol to minimize middle ear barotrauma.
INTRODUCTION
Middle ear barotrauma (MEB) remains a common com-
plication of hyperbaric oxygen (HBO2) therapy, with 
the incidence ranging from 8%-68.7% [1, 2]. Currently, 
three concurrent practices are used to reduce the 
incidence of MEB: 
i) assessment to identify patient at risk of MEB; 
ii) teaching patients correct ear equalization techniques; 
iii) slow chamber compression. 
Vahidova et al demonstrated that the use of a slow com-
pression technique (1.1 meters/minute vs. 2.8 meters/
minute) significantly reduced the incidence of middle 
ear barotrauma from 52.3% to 28.5% [3]. Most centers 
compress their patients to 242 kilopascals/kPa, or 2.4 
atmospheres absolute/ATA over 10 to 14 minutes de-
pending on patients’ comfort and on their ability to 
equalize their ears. These compressions are linear at a set 
rate, with interruptions whenever a patient volunteers 
difficulty with ear equalization (pain or discomfort). One 
center (personal communication) routinely uses staged 
compression in its treatment protocol in an attempt to 
identify patients with equalization problems, as well as 
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to allow patients time to “catch up” with equalization. 
It is postulated that staged compression will result in a 
lower incidence of middle ear barotrauma with result-
ing improvement of patient comfort. Currently there is 
hardly any literature on this topic. The aim of the study 
was to evaluate whether a staged chamber compression 
protocol (trial regimen) during HBO2 therapy is able 
to reduce the incidence of middle ear barotrauma to 
10% versus an estimated 30% experienced under a 
linear chamber compression protocol (standard regimen). 
This study was conducted in a multiplace chamber. 
METHODOlOgy
Ethics approval
Ethics approval for this trial was obtained from The 
Townsville Hospital Human Research Ethics Committee 
(HREC reference number: HREC/12/QTHS/78). The 
trial was registered with the Australian New Zealand 
Clinical Trials Registry (ACTRN12612000724875).
Study protocol
This was a single-center, double-blinded, balanced 
randomized, parallel group trial involving 100 new 
patients older than 18 years old, presenting for their 
first session of HBO2 therapy. Informed consent was 
obtained from all participants prior to the start of the 
study. Exclusion criteria were previous HBO2 treatment, 
contraindications for HBO2, patients with grommets/
active otological conditions requiring grommets, 
existing tympanic membrane rupture, unconscious 
patients and any prescribed hyperbaric treatment table 
other than to 242 kPa (2.4 ATA).
 Participants were randomly assigned in a balanced 
and blocked manner to undergo a staged compression 
protocol or a linear compression protocol on their first 
HBO2 treatment. This study was done in a multiplace 
chamber with each participant in a sitting position. 
Staged compression protocol
1. 101.3 kPa (1 ATA) to 129.7 kPa (1.28 ATA) 
 @ 1.4 meters/minute for two minutes; 
 hold pressure for one minute.
2. 129.7 kPa (1.28 ATA) to 172.3 kPa (1.7 ATA) 
 @ 1.4 meters/minute  for three minutes; 
 hold pressure for one minute.
3. 172.3 kPa (1.7 ATA) to 242.0 kPa (2.4 ATA) 
 @ 1.4 meters/minute for five minutes.
Total descent time = 12 minutes.
linear compression protocol
1. 101.3 kPa (1 ATA) to 242.0 kPa (2.4 ATA) 
 @ 1.1 meters/minute.
Total descent time = 12 minutes, 43 seconds.
 Staged compression protocol is presented in Figure 1.
 For both protocols, participants were continuously 
encouraged by the in-chamber hyperbaric nurse to 
perform ear equalization (any preferred technique: 
Valsalva, Frenzel, Toynbee, Lowry, Edmonds, swallowing 
saliva, drinking water, yawning, wiggling of jaw move-
ment) as per usual practice. During the holding stage, 
continuous inflow and outflow flushing of the chamber 
was performed to create an illusion of compression, as a 
method of blinding the participant. The ascent rate at the 
end of the treatment was 0.95 atm/minute (15 minutes 
from 14 meters to surface). The study was confined to 
observation of the participants’ first HBO2 treatment 
only.
 Tympanic membranes (TM) of each participant were 
photographed pre- and post-hyperbaric treatment with 
a Welch Allyn Digital Macroview Otoscope by trained 
staff members using standard mode (no magnification) 
and auto white balance, producing pictures with a reso-
lution of 1280 x 1024 megapixels in JPEG format. 
Pre-treatment photographs (left and right ears) were 
taken immediately prior to entering the hyperbaric 
chamber and post-treatment photographs taken within 
10 minutes of the participant exiting the hyperbaric 
chamber. Each photograph was assigned a random 
number. Any earwax impeding the view was removed 
during the pre-treatment assessment – i.e., before any 
photograph was taken. All photographs were assessed 
and graded using modified TEED score by one single 
experienced otolaryngologist, who was blinded and not 
involved in the clinical care of the participants. 
Study outcomes
Primary outcome was incidence of MEB defined as an 
increase by at least one grade in modified TEED score 
in one or both ears. Secondary outcomes were severity 
of MEB, objective experience of pain, number of inter-
rupted treatments, and number of aborted treatments. 
Interrupted treatment was defined as a pause in the 
compression protocol due to a participant experiencing 
ear pain/discomfort but successfully arriving at 242 kPa 
(2.4 ATA) (any interruption of treatment by another 
patient during the HBO2 treatment was recorded as an 
interrupted treatment). Aborted treatment was defined 
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figure 1: Staged compression protocol
__________________________________________________________________________________________________________________________
  TiME 0 1 2 3 4 5 6 7 8 9 10 11 12 13
  (minutes)
__________________________________________________________________________________________________________________________
  DEPTH  0 1.4 2.8 2.8 4.2 5.6 7 7 8.4 9.8 11.2 12.6 14 14
 (meters)
__________________________________________________________________________________________________________________________
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as a treatment terminated before reaching 242 kPa 
(2.4 ATA) after three failed attempts to equalize the 
ears. Pain score was recorded on a numerical rating 
scale, rated directly upon reaching treatment depth or 
when treatment was aborted. A structured self-admin-
istered questionnaire was also used prior to HBO2 treat-
ment to record basic demographic data and potential 
confounders.
Statistical analysis
Sample size calculations revealed that group sample sizes 
of 50 in each group will achieve a power in the excess 
of 80% to detect a reduction in the incidence of middle 
ear barotrauma on otoscopic examination from 30% in 
the standard (control) group (linear compression) to 
10% in the intervention group (staged compression) at a 
one-sided significance level of 5% (P < 0.05). A one-sided 
test was chosen since we were exclusively interested in 
whether the new staged compression was able to achieve 
a significant improvement when compared to the glob-
ally accepted linear compression currently in place.
 A balanced, blocked randomization procedure was 
employed by generating the allocation list based on a 
random seed using a statistical package and produced 
by a statistician with no clinical involvement in the trial. 
The allocation list was blocked (N=20) so that after each 
block of 20 participants the randomization was balanced. 
From the allocation list, sequentially numbered, opaque, 
sealed and stapled envelopes containing the random 
allocation for the single participant were produced. 
Corresponding envelopes were opened only after the 
enrolled participant was inside the hyperbaric chamber 
and the chamber door closed. Envelopes were opened 
by the chamber operator of the day and the noted regi-
men applied. Participants, inside nurses, outside nurses 
and attending hyperbaric doctors were blinded to alloca-
tion. Assignment of intervention was known only to the 
chamber operator, who was not involved in the clinical 
management or assessment of the participant. The con-
trol console of the chamber showing the compression 
rate and depth was masked by cardboard and could be 
seen only by the chamber operator. The depth gauge 
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RESUlTS
From September 2012 to December 2014, a total of 
201 new patients were treated in the chamber. Of these 
patients, 50 were assigned to each staged and linear com-
pression protocols, while 101 patients were excluded 
for various reasons (Figure 2). There were 74 males and 
26 females with a median age of 61 years (interquartile 
range 50 – 69). Baseline characteristics and confounders 
proved to be similar for the two groups (Table 1).
 MEB was detected in 24 of 50 participants (48.0%) in 
the staged compression group compared with 31 of 50 
participants (62.0%) in the linear compression group 
when an increase by at least one grade was used as the 
definition of MEB. This observed difference did not 
reach statistical significance (P=0.12). A more specific 
post-hoc analysis taking the degree of deterioration in 
TEED grades into consideration showed that the staged 
protocol resulted in significantly fewer severe grades 
when compared to the linear protocol (P=0.028, exact 
one-sided Mann-Whitney type test, Table 2). It espe-
cially revealed that not a single participant in the inter-
vention arm experienced a deterioration by more than 
two grades, compared to 12% (N=6) in the control arm. 
 The secondary outcomes (interrupted treatment 
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inside the chamber was covered with opaque plastic 
during the treatment. During the hold stage of the staged 
protocol, continuous inflow and outflow flushing was 
done to create an illusion of compression. The oto-
laryngologist assessing the TM photographs was also 
blinded to allocation.
 Statistical data collected was analyzed using SPSS 
Version 20. Standard univariate and bivariate statistical 
procedures were employed during the analysis. For 
descriptive purposes, percentages were used for cate-
gorical variables and means (standard deviation) or 
medians (interquartile ranges) were employed for nu-
merical variables depending on fulfilment of normality 
assumptions. The incidences of the main outcome mea-
sure were compared between the treatment groups by 
means of exact binomial tests. The same procedure was 
used to assess the categorical secondary outcome mea-
sures. The numerical subjective pain ratings were com-
pared between the groups by non-parametric Mann-
Whitney tests since the distribution proved to be highly 
skewed. Bivariate assessments of potential confounders 
were assessed by following the same analytical proce-
dures. If adjustment for confounder(s) seemed neces-
sary, binary logistic regression modeling was employed.
_______________________________________________________________________________________________________
Table 1: Baseline characteristics
   STAGED (N=50) LINEAR (N=50) P-VALUE
 age in years (mean (sD)) 60.5 (15.8) 59.1 (12.6) P=0.63
_______________________________________________________________________________________________________
 gender (male:female) 40:10 34:16 P=0.25
_______________________________________________________________________________________________________
 smoking 
     non-smokers  24.0% (N=12) 26.0% (N=13) P=0.89
     ex-smokers  52.0% (N=26) 52.0% (N=26) 
     active smokers  24.0% (N=12) 22.0% (N=11) 
_______________________________________________________________________________________________________
 scuba divers  20.0% (N=10) 10.0% (N=5) P=0.26
_______________________________________________________________________________________________________
 history of ENT surgery 22.0% (N=11) 32.0% (N=16) P=0.37
_______________________________________________________________________________________________________
 history of recent ENT infection 10.0% (N=5) 18.0% (N=9) P=0.39
_______________________________________________________________________________________________________
 recent URTI* nil nil 
_______________________________________________________________________________________________________
 history of head/neck radiation  20.0% (N=10) 12.0% (N=6) P=0.41
 (HBO2 indication for treatment 
 or prevention of ORN)  
_______________________________________________________________________________________________________
 otoscopic confirmation  77.6% (N=38) 64.0% (N=32) P=0.19
 of tympanic membrane 
 movement on Valsalva 
_______________________________________________________________________________________________________
 * urTi = upper respiratory tract infection
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and aborted treatment) were not affected by the use of 
staged compression. Eight participants (16.0%) in the 
staged group versus 12 (24.0%) in the linear group ex-
perienced interrupted treatment (P=0.317), while one 
participant (2.0%) in the staged group and three par-
ticipants (6.0%) in the linear group had their treatment 
aborted (P=0.307). Pain-free hyperbaric treatment 
was reported in 84% (N=42) under the staged proto-
col and 88% (N=44) under the linear protocol (P=0.77). 
 Overall, 14 participants reported pain scores reach-
ing from 3 to 9 (with a total of three participants in 
each protocol reporting a score above 5 on a scale of 1 
to 10). Reported pain scores did not differ significantly 
between the compression regimen; exact Mann-Whit-
ney type test P=0.491. There was a slightly lower mean 
rank (lower pain score) under the staged protocol (mean 
rank 6.8) than under the linear protocol (mean rank 
8.4).
___________________________________________________________________________________________________________________________________________________________
figure 2: CONSORT participants’ flow through the trial
assessed for eligibility (n=201) excluded (n=101)
a) inclusion criteria not met (n=24) 
 – previous HBO2
b) exclusion criteria met (n=63) 
 – prescribed treatment table not 2.4 ATA (n=41)
randomized (n=100)
staged compression protocol (intervention group)
analyzed (n=50)
linear compression protocol (control group)
analyzed (n=50)
▶
▼
▼
▼
▼
▼
▼
_________________________________________________________________________________________________________________________________
Table 2: MEB by protocol and absolute deterioration in grades
_________________________________________________________________________________________________________________________________
  MEB grade deterioration
_________________________________________________________________________________________________________________________________
 protocol no MEB  MEB MEB MEB total
  (no deter- deterioration deterioration deterioration
  ioration) by 1 grade by 2 grades by 3 grades 
_________________________________________________________________________________________________________________________________
 linear 38.0% (N=19) 34.0% (N=17) 16.0% (N=8) 12.0% (N=6) 100.0% (N=50)
_________________________________________________________________________________________________________________________________
 staged 52.0% (N=26) 32.0% (N=16) 16.0% (N=8) 0.0% 100.0% (N=50)
_________________________________________________________________________________________________________________________________
 Overall, 51.7% of those with no observable TM move-
ment developed MEB compared with 55.7% (P=0.83) 
in those with TM movement. A higher percentage 
(62.5% vs. 53.6%) of participants with a history of 
head and neck radiation developed MEB in our study, 
though this was not statistically significant (P=0.591). 
There was, however, a higher percentage of interrupted 
treatments in this subgroup, 37.5% vs. 16.7%, though 
 again no statistical difference was found (P=0.084).
DISCUSSION
MEB during compression is caused by a reduction in 
middle ear volume based on Boyle’s law. Active man-
euvers (e.g., Valsalva) to open the Eustachian tubes are 
usually required to equalize middle ear pressure. Thus, 
not surprisingly a slower compression will allow time 
for patients to perform the active maneuvers and 
reduce the rate of MEB as demonstrated by Vahido-
va, et al. [3]. As the pressure gradient increases, these 
active maneuvers become increasingly difficult to per-
form [4, 5]. In a linear compression, a patient may be 
too slow in performing these active maneuvers, and 
MEB may have occurred before any intervention such 
as interrupting the compression. This is more likely 
to happen in a new patient undergoing the first hy-
perbaric compression due to unfamiliarity. By having 
stopping stages during the compression, the patient may 
be able to have more time to equalize the middle ear 
pressure before the Eustachian tube becomes blocked. 
 We designed our staged compression protocol based 
on the following: 
i)  both protocols to have similar total compression 
 time (12 minutes vs. 12 minutes 43 seconds, which 
 should have insignificant effect on MEB incidence); 
ii)  uncomplicated compression protocol with practical 
 stopping stages for our chamber operators (time 
 and number of stops); and 
iii) pressures where new patients usually start having 
 trouble with ear equalization. 
At our center, the majority of new patients develop ear 
equalization problems at around 121.6-136.8 kPa (1.2-
1.35 ATA). This was calculated as 16%-25% middle ear 
volume change assuming no active ear equalization 
was being done. We thus choose 129.7 kPa (1.28 ATA) 
and 172.3 kPa (1.7 ATA) as our stopping stages, cor-
responding to a maximum 22% and 25% volume change 
respectively.
 In this trial, the use of a staged compression proto-
col, as compared with a standard linear compression 
protocol, did not reduce the incidence of MEB, when 
defined as any deterioration (i.e., an increase in modi-
fied TEED score by a single grade – e.g., from 0 to 1), 
in a participant’s first hyperbaric oxygen treatment. 
The rates of secondary outcomes (pain, interrupted 
treatments and aborted treatments) were also similar. 
However, in a more specific analysis – i.e., taking the 
degree of deterioration into account, the staged com-
pression protocol resulted in significantly less severe 
deteriorations in grades when compared to the linear 
compression protocol (P=0.028; exact one-sided Mann-
Whitney type test). In this context it seems noteworthy 
that not a single participant in the staged compression 
group suffered a severe deterioration (exceeding 2 MEB 
grades), compared with 12% (N=6) in the linear com-
pression group.
 We offer two possible explanations for these find-
ings. First, our chosen depth and assumed middle ear 
volume change for the holding stage may be inappro-
priate. Change in pressure and volume during chamber 
compression is a continuous process. Furthermore, 
the  percentage of change in volume is greater at lower 
pressures. Thus, a different staged compression protocol 
may be more appropriate – i.e., an earlier, longer initial 
holding period; and more than two stages. However, this 
may result in longer total compression time and make 
comparison more challenging. Alternatively, an expo-
nential compression protocol with an initial slow com-
pression and increasing rate of compression over time 
could be considered. Calculation of these types of 
protocols, however, seems difficult, especially for the 
exponential compression protocol. An exponential 
compression protocol would also be very challenging to 
implement manually by a chamber operator and would 
require modern computer controlled compression. 
 Secondly, as both the participants and in-chamber 
nurses were blinded to allocation, the benefit of extra 
attention by the in-chamber nurse to encourage the 
participant to perform active maneuvers during the 
holding stage may have been lost. 
  The incidence of MEB in our participants who un-
derwent the linear compression protocol was 62%. 
This was within range of the incidences reported in the 
literature [1, 2] and is reflective of different patient pop-
ulation, criteria for grading MEB and inter-observer 
factors. However, compared with Vahidova’s study, our 
MEB incidence was relatively high. This can be explained 
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CONClUSION
The use of a staged compression protocol for the 
first hyperbaric oxygen treatment was not superior 
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to minimize MEB, pain and treatment interruptions.
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